The FDA clearance to market was based upon data showing DR-70 (FDP) has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy confirmed with this disease.
Gary Dreher, CEO of AMDL, said: “This clearance to market provides CRC patients with access to a potentially lifesaving test. Post-surgery testing with DR-70 is a valuable aid in monitoring disease progression in patients previously diagnosed with colorectal cancer.”